^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Non Small Cell Lung Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.
    Secondary therapy:
    Chemotherapy
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Non-Small Cell Lung Cancer: Useful in Certain Circumstances...Bevacizumab/carboplatin/pemetrexed...Bevacizumab/cisplatin/pemetrexed....Bevacizumab/carboplatin/paclitaxel...
    Secondary therapy:
    carboplatin + paclitaxel; cisplatin + pemetrexed; carboplatin + pemetrexed